目的 探討玉泉丸聯(lián)合達格列凈片治療2型糖尿病的臨床療效。方法 選取2016年9月-2019年12月河南中醫(yī)藥大學第一附屬醫(yī)院收治的98例2型糖尿病患者，將所有患者隨機分為對照組和治療組，每組各49例。對照組早餐前口服達格列凈片，5~10 mg/次，1次/d。治療組在對照組基礎上飯后服用玉泉丸，6 g/次，4次/d。兩組患者均連續(xù)治療3個月。觀察兩組的臨床療效，比較兩組的血糖指標、胰島素指標、炎癥因子。結(jié)果 治療后，治療組的總有效率（95.92%）較對照組（79.59%）高（P<0.05）。治療后，兩組白細胞介素-6（IL-6）、C反應蛋白（CRP）、腫瘤壞死因子-α（TNF-α）水平較治療前降低（P<0.05）；且治療組炎癥因子水平低于對照組（P<0.05）。治療后，兩組患者空腹血糖（FPG）、餐后2 h血糖（2 h PG）、糖化血紅蛋白（HbA1c）較治療前降低（P<0.05）；且治療組血糖指標低于對照組（P<0.05）。治療后，兩組胰島素抵抗指數(shù)（HOMA-IR）較治療前降低，胰島素（FINS）、胰島β細胞功能指數(shù)（HOMA-β）較治療前升高（P<0.05）；且治療組HOMA-IR低于對照組，F(xiàn)INS、HOMA-β高于對照組（P<0.05）。結(jié)論 玉泉丸聯(lián)合達格列凈片治療2型糖尿病可改善患者血糖及胰島素分泌，減輕炎癥反應，且安全較好。

Objective To investigate the clinical effect of Yuquan Pills combined with Dapagliflozin Tablets in treatment of type 2 diabetes mellitus. Methods Patients (98 cases) with type 2 diabetes mellitus in the First Affiliated Hospital of Henan University of CM from September 2016 to December 2019 were randomly divided into control and treatment groups, and each group had 49 cases. Patients in the control group were po administered with Dapagliflozin Tablets, 5-10 mg/time, once daily. Patients in the treatment group were po administered with Yuquan Pills on the basis of the control group, 6 g/time, four times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and blood glucose index, insulin index, and inflammatory factors in two groups were compared. Results After treatment, the total effective rate of the treatment group (95.92%) was higher than that of the control group (79.59%) (P<0.05). After treatment, the levels of IL-6, CRP, and TNF-α in the two groups were lower than those before treatment (P<0.05), and the levels of inflammatory factors in the treatment group were lower than those in the control group (P<0.05). After treatment, the FPG, 2 h PG, and HbA1c of the two groups were lower than those before treatment (P<0.05), and the blood glucose index of the treatment group was lower than that of the control group (P<0.05). After treatment, the HOMA-IR of two groups were decreased, but the FINS and HOMA-β of two groups were increased (P<0.05). After treatment, the HOMA-IR of the treatment group was lower than that of the control group, but the FINS and HOMA-β of the treatment group were higher than that of the control group (P<0.05). Conclusion Yuquan Pills combined with Dapagliflozin Tablets in treatment of type 2 diabetes mellitus can improve blood glucose and insulin secretion, and reduce inflammatory reaction with good safety.

R977

河南省中醫(yī)藥科學研究專項課題（2019 JDZX2105）